Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Devices & Dosimetry

Comparison of the efficacy and safety of a 730-nm picosecond titanium sapphire laser and a 1064-nm picosecond neodymium yttrium aluminum garnet laser for the treatment of acquired bilateral nevus of Ota-like macules: A split-face, evaluator-blinded, randomized, and controlled pilot trial

The 730-nm PTSL is more effective than the 1064-nm PNYL in the treatment of ABNOM.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors compared a 730-nm picosecond titanium sapphire laser with a 1064-nm picosecond Nd:YAG laser in a split-face trial of 15 participants with acquired bilateral nevus of Ota-like macules, with blinded visual evaluations. They report that the 730-nm side showed greater improvement at 24 weeks, with no significant difference in pain or satisfaction between the two lasers.

Participants
15
Who or what was studied
Fifteen participants with acquired bilateral nevus of Ota-like macules (ABNOM)
Wavelengths
730, 1064 nm
Limits stated in the abstract
The abstract describes a small pilot trial and does not report a sample size calculation or details of the blinded evaluation beyond visual assessment.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

The picosecond neodymium yttrium aluminum garnet laser (PNYL) has been successfully used in treating acquired bilateral nevus of Ota-like macules (ABNOM). The 730-nm picosecond titanium sapphire laser (PTSL) is an emerging tool for pigmentary disorders. However, no studies have compared two different wavelengths of picosecond laser for the treatment of ABNOM.

Aims

To compare the efficacy and safety of the 730-nm PTSL with the 1064-nm PNYL in the treatment of ABNOM.

Methods

Fifteen participants with ABNOM were randomized to undergo a single session of either the 730-nm PTSL on one side of the face and 1064-nm PNYL on the other side. Efficacy and safety assessments were performed by blinded visual evaluations at baseline, 12 weeks, and 24 weeks posttreatment. Participants' satisfaction and adverse effects were recorded.

Results

Compared to baseline, The 730-nm PTSL-treated side showed better improvement than that of the 1064-nm PNYL-treated side at 24 weeks posttreatment (1.67 ± 1.047 vs. 0.87 ± 0.640, p = 0.027). There were no significant differences in pain sensation and participants' satisfaction between the two laser treatments.

Conclusions

The 730-nm PTSL is more effective than the 1064-nm PNYL in the treatment of ABNOM.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Laser. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies